WO2005123130A3 - Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor - Google Patents
Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor Download PDFInfo
- Publication number
- WO2005123130A3 WO2005123130A3 PCT/DK2005/000403 DK2005000403W WO2005123130A3 WO 2005123130 A3 WO2005123130 A3 WO 2005123130A3 DK 2005000403 W DK2005000403 W DK 2005000403W WO 2005123130 A3 WO2005123130 A3 WO 2005123130A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rheumatic
- combinations
- lipoxygenase inhibitor
- arthritic diseases
- improved treatments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200400948 | 2004-06-17 | ||
DKPA200400948 | 2004-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005123130A2 WO2005123130A2 (en) | 2005-12-29 |
WO2005123130A3 true WO2005123130A3 (en) | 2006-02-02 |
Family
ID=34969752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2005/000403 WO2005123130A2 (en) | 2004-06-17 | 2005-06-17 | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005123130A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044451A1 (en) * | 2004-10-19 | 2006-04-27 | Eli Lilly And Company | Treatment of osteoarthritis and dosing regimen for arzoxifene |
EP1947942B1 (en) * | 2005-08-18 | 2015-07-29 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
CN101229154B (en) * | 2007-01-26 | 2010-05-12 | 鲁南制药集团股份有限公司 | Medicine compounds for treating osteoporosis |
FR2953139B1 (en) * | 2009-11-27 | 2012-04-13 | Servier Lab | PHARMACEUTICAL COMPOSITION COMPRISING STRONTIUM SALT, VITAMIN D AND CYCLODEXTRIN |
WO2011156518A2 (en) | 2010-06-10 | 2011-12-15 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
CN103221052A (en) | 2010-09-16 | 2013-07-24 | 施摩达生物技术有限公司 | Fulvestrant compositions and methods of use |
NL2016848B1 (en) | 2016-05-27 | 2017-12-04 | Oudshoorn Berendina | Use of a bisphophosphonate salt in a medicament for a naturally occurring disease/disorder in a mammal. |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0440809A1 (en) * | 1989-08-18 | 1991-08-14 | Toray Industries, Inc. | Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient |
WO1997029776A1 (en) * | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
WO2002026239A1 (en) * | 2000-09-26 | 2002-04-04 | Temple University Of The Commonwealth System Of Higher Education | Analgesic and glucosamine compositions |
WO2003020267A1 (en) * | 2001-08-30 | 2003-03-13 | Merckle Gmbh | Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration |
WO2003066048A2 (en) * | 2002-02-08 | 2003-08-14 | F. Hoffmann-La Roche Ag | Use of 15-lipoxygenase inhibitors for treating and preventing bone loss |
WO2003082188A2 (en) * | 2002-03-27 | 2003-10-09 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
EP1400243A1 (en) * | 2002-09-19 | 2004-03-24 | Tanabe Seiyaku Co., Ltd. | Calcium-activated K channel activator |
-
2005
- 2005-06-17 WO PCT/DK2005/000403 patent/WO2005123130A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0440809A1 (en) * | 1989-08-18 | 1991-08-14 | Toray Industries, Inc. | Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient |
WO1997029776A1 (en) * | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
WO2002026239A1 (en) * | 2000-09-26 | 2002-04-04 | Temple University Of The Commonwealth System Of Higher Education | Analgesic and glucosamine compositions |
WO2003020267A1 (en) * | 2001-08-30 | 2003-03-13 | Merckle Gmbh | Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration |
WO2003066048A2 (en) * | 2002-02-08 | 2003-08-14 | F. Hoffmann-La Roche Ag | Use of 15-lipoxygenase inhibitors for treating and preventing bone loss |
WO2003082188A2 (en) * | 2002-03-27 | 2003-10-09 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
EP1400243A1 (en) * | 2002-09-19 | 2004-03-24 | Tanabe Seiyaku Co., Ltd. | Calcium-activated K channel activator |
Non-Patent Citations (3)
Title |
---|
BRADY H R ET AL: "Lipoxins: Putative braking signals in best defense, inflammation and hypersensitivity", CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION 1996 UNITED STATES, vol. 5, no. 1, 1996, pages 20 - 27, XP008051486, ISSN: 1062-4821 * |
CHARLIER C ET AL: "Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 38, no. 7-8, July 2003 (2003-07-01), pages 645 - 659, XP004448316, ISSN: 0223-5234 * |
VANDERHOEK J Y ET AL: "Endogenous hydroxyeicosatetraenoic acids stimulate the human polymorphonuclear leukocyte 15-lipoxygenase pathway", JOURNAL OF BIOLOGICAL CHEMISTRY 1985 UNITED STATES, vol. 260, no. 29, 1985, pages 15482 - 15487, XP008051490 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2005123130A2 (en) | 2005-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005123130A3 (en) | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor | |
GB0412753D0 (en) | Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis | |
IL185462A0 (en) | New pharmaceutical compositions useful in the treatment of pain | |
IL172773A0 (en) | Formulations for the treatment of arhritis conditions | |
MXPA04001876A (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis. | |
WO2008024978A3 (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
HK1134788A1 (en) | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health | |
PT2054045E (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain | |
RS20060662A (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
NZ591496A (en) | A medicinal comprising ibuprofen and paracetamol and treatment for arthritis | |
MY148277A (en) | Treatment of cartilage disorders with fgf-18 | |
MY149863A (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
WO2005011721A3 (en) | Use of a pak inhibitor for the treatment of a joint disease | |
MX2008011454A (en) | Novel use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses. | |
WO2007044321A3 (en) | Latent procytotoxins and uses thereof | |
WO2008024970A3 (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
WO2007059874A3 (en) | Compositions for the treatment of osteoarthritis and to nourish the synovial fluid | |
WO2007031853A3 (en) | Therapeutic combination of hamlet and a hdac inhibitor to treat cancer | |
GB0406912D0 (en) | Pharmaceutical composition for prophylaxis or treatment of osteoporosis and method to prepare the same | |
WO2007144889A3 (en) | Treatment of neurofibromatosis | |
WO2003080568A3 (en) | Probucol derivatives | |
WO2009041799A9 (en) | Pharmaceutical composition combining diacerein and chondroitin sulphate and use thereof in the treatment of osteoarthritis and related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |